Is it? I can’t find much real data, and, at least in the US, monkeypox surveillance appears to be at least as poor as COVID surveillance early in the pandemic.
Is there near term availability of enough doses of a nice vaccine (e.g. MVA-BN/Imvanex/Jynneos) to vaccinate the entire MSM population?
The US has a large stockpile of ACAM2000, but it is unpleasant, potentially dangerous, and has at least a mild FDA warning for use in patients with HIV.
They based the decision on data showing that almost all cases involve that demographic.